In Pharmaceutical Commerce, Matt Wolf, Chief Commercial Officer at CareTria, shares perspective on the shift from high-volume small molecule distribution to high-cost, specialty, and temperature-sensitive therapies that require greater precision and control.
The conversation also reflects on how pandemic-era disruption strengthened business continuity planning, accelerated warehouse automation, and elevated expectations around resilience and redundancy across the supply chain.
Read the full article here.
